Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19.
Simon Paul GrahamRebecca K McLeanAlexandra J SpencerSandra Belij-RammerstorferDaniel WrightMarta UlaszewskaJane C EdwardsJack W P HayesVeronica MartiniNazia ThakurCarina ConceicaoIsabelle DietrichHolly SheltonRyan WatersAnna B LudiGinette WilsdenClare BrowningDagmara BialySushant BhatPhoebe Stevenson-LeggettPhilippa HollinghurstCiaran GilbrideDavid PulidoKaty MoffatHannah R SharpeElizabeth R AllenValerie MiouletChris ChiuJoseph NewmanAmin S AsforAlison BurmanSylvia CrossleyJiandong HuoRaymond J OwensMiles CarrollJohn A HammondElma TchilianDalan BaileyBryan CharlestonSarah C GilbertTobias J TuthillTeresa LambePublished in: NPJ vaccines (2020)
Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres.